These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20388858)

  • 1. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.
    Walthour A; Seymour L; Tackett R; Perri M
    Ann Pharmacother; 2010 May; 44(5):809-18. PubMed ID: 20388858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
    Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
    Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.
    Law MR; Ross-Degnan D; Soumerai SB
    Psychiatr Serv; 2008 May; 59(5):540-6. PubMed ID: 18451014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment: Assessment of Changes in Utilization of Health-Care Services After Implementation of a Prior Authorization Policy for Atypical Antipsychotic Agents.
    Faden L; Soumerai SB
    Ann Pharmacother; 2011 Feb; 45(2):283. PubMed ID: 21304028
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment: Assessment of Changes in Utilization of Health-Care Services After Implementation of a Prior Authorization Policy for Atypical Antipsychotic Agents.
    Scully JH
    Ann Pharmacother; 2011 Feb; 45(2):282. PubMed ID: 21304022
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications.
    Al-Zakwani IS; Barron JJ; Bullano MF; Arcona S; Drury CJ; Cockerham TR
    Curr Med Res Opin; 2003; 19(7):619-26. PubMed ID: 14606985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.
    Soumerai SB; McLaughlin TJ; Ross-Degnan D; Casteris CS; Bollini P
    N Engl J Med; 1994 Sep; 331(10):650-5. PubMed ID: 8052275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
    J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.
    Hartung DM; Touchette DR; Ketchum KL; Haxby DG; Goldberg BW
    Clin Ther; 2004 Sep; 26(9):1518-32. PubMed ID: 15531015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
    Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
    Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
    Sankaranarayanan J; Puumala SE
    Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.
    Lafeuille MH; Gravel J; Lefebvre P; Fastenau J; Muser E; Doshi D; Duh MS
    J Med Econ; 2013 Nov; 16(11):1290-9. PubMed ID: 24006903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of antipsychotic medication on psychiatric service utilization and cost.
    Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
    J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.
    Signorovitch J; Birnbaum H; Ben-Hamadi R; Yu AP; Kidolezi Y; Kelley D; Phillips G; Lawson A; Ball DE
    J Clin Psychiatry; 2011 Jun; 72(6):787-94. PubMed ID: 21294993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth.
    Spence O; Reeves G; dosReis S
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1064-1071. PubMed ID: 32558177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts.
    Martin BC; Miller LS; Kotzan JA
    Schizophr Res; 2001 Mar; 47(2-3):281-92. PubMed ID: 11278146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.